UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Endo International plc

(Name of Issuer)

Ordinary Shares, nominal value \$0.0001 per share

(Title of Class of Securities)

G30401106

(CUSIP Number)

Clive Bode 301 Commerce Street, Suite 3300 Fort Worth, TX 76102 (817) 871-4000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 19, 2016

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ⊠

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7(b) for other parties to whom copies are to be sent.

(Continued on following pages)

(Page 1 of 8 Pages)

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

^{*}The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

SCHEDULE 13D

Page	2	of _	8	Pages	

1	NAMES OF RE	PORTING PERSO	NS			
_	TPG Group Hol	dings (SBS) Adviso	rs, Inc.			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)					
	$\stackrel{\prime}{}$ (a) \square					
	(b) □					
3	SEC USE ONL	Y				
4	SOURCE OF F	UNDS (see instructi	ons)			
	OO (See Item 3))				
5	CHECK BOX I	F DISCLOSURE O	F LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) \Box			
6	CITIZENSHIP	OR PLACE OF OR	GANIZATION			
0	Delaware					
NILIMEDE	D OF CHARE	7	SOLE VOTING POWER			
NUMBE	ER OF SHARES	/	- 0 -			
DEM	EELCIALIS/	8	SHARED VOTING POWER			
BENEFICIALLY OWNED BY		0	22,152,136			
			* *			
	REPORTING	9	SOLE DISPOSITIVE POWER			
P	ERSON		- 0 -			
	WITH	10	SHARED DISPOSITIVE POWER			
		10	22,152,136			
11	AGGREGATE .	AMOUNT BENEFI	CIALLY OWNED BY EACH REPORTING PERSON			
11	22,152,136					
12	CHECK BOX I	ETHE ACCRECAT	FE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)			
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) □					
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)					
13	9.9%*					
14	TYPE OF REPORTING PERSON					
14	CO					

^{*} The calculation assumes that there is a total of 222,661,344 Ordinary Shares ("<u>Ordinary Shares</u>") of Endo International plc (the "<u>Issuer</u>") outstanding as of April 29, 2016, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "<u>Commission</u>") on May 6, 2016.

CUSIP No. <u>G30401106</u>				SCHEDUL	E 13D	Page <u>3</u> of <u>8</u> Pages	
			•				
1	TPG Advisors VI, Inc.						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)						
	(a) □						
	(b) 🗆		_				
3	SEC US	E ONLY					
4	SOURC	E OF FU	JNDS (see instructi	ons)			
	OO (See						
5	CHECK	BOX IF	F DISCLOSURE O	F LEGAL PROCEEDINGS IS RE	EQUIRED PURSU	ANT TO ITEMS 2(d) or 2(e) \square	
6	CITIZENSHIP OR PLACE OF ORGANIZATION						
Delaware							
NUMBER OF		7	SOLE VOTING	POWER			
SHA	RES		- 0 -				
BENEFIC	CIALLY	8	SHARED VOTI	IG POWER			
OWNED BY			22,152,136				
EACH		9	SOLE DISPOSIT	IVE POWER			
REPOR	TING		- 0 -				
PERS	SON						
WIT	ГН	10	SHARED DISPO	SITIVE POWER			
	22,152,136						
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		DN					
	22,152,1	.36					
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) □						

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13

14

9.9%*

CO

TYPE OF REPORTING PERSON

^{*} The calculation assumes that there is a total of 222,661,344 Ordinary Shares outstanding as of April 29, 2016, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Commission on May 6, 2016.

CUSIP No. <u>G30401106</u>				SCHEDULE 13D	Page <u>4</u> of <u>8</u> Pages		
1	NAMES OF REPORTING PERSONS						
	David Bond	derman					
2	CHECK TH	HE APPI	ROPRIATE BOX	IF A MEMBER OF A GROUP (see instructions)			
					(a) □		
					(b) □		
3	SEC USE C	ONLY					
4	SOURCE C	OF FUN	DS (see instruction	ns)			
	OO (See Ite						
5	CHECK BO	OX IF D	ISCLOSURE OF	LEGAL PROCEEDINGS IS REQUIRED PURSUANT	`TO ITEM 2(d) or 2(e) □		
6	CITIZENS	HIP OR	PLACE OF ORG	ANIZATION			
	United States of America						
NUMBER OF 7 SOLE VOTING		SOLE VOTING	G POWER				
_	SHARES -0-		-0-				
	BENEFICIALLY		SHARED VOTING POWER				
OW	NED BY		22,152,136				
	EACH REPORTING 9		SOLE DISPOSITIVE POWER				
PE	ERSON		-0-				
WITH		10	SHARED DISPOSITIVE POWER				
	_		22,152,136				
11 AGGREGATE AMOUNT BENEFICIALLY OWNED		IALLY OWNED BY EACH REPORTING PERSON					
	22,152,136						
12	CHECK BO	OX IF T	HE AGGREGATI	E AMOUNT IN ROW (11) EXCLUDES CERTAIN SH	ARES (see instructions)		
13	PERCENT	OF CLA	ASS REPRESENT	ED BY AMOUNT IN ROW (11)			

The calculation assumes that there is a total of 222,661,344 Ordinary Shares outstanding as of April 29, 2016, as reported in the Issuer's Quarterly

9.9%*

TYPE OF REPORTING PERSON

Report on Form 10-Q filed with the Commission on May 6, 2016.

14

CUSIP N	No. <u>G30401106</u>	SCHEDULE 13D	Page <u>5</u> of <u>8</u> Pages
•			·
1	NAMES OF REPORTING PERSON	S	
	James G. Coulter		
2	CHECK THE APPROPRIATE BOX	IF A MEMBER OF A GROUP (see instructions)	
			(a) 🗀

2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)					
			(a) 🗆			
			(b) □			
3	SEC USE C	ONLY				
4	SOURCE C	F FUNI	OS (see instructions)			
	OO (See Ite	em 3)				
5	CHECK BO	OX IF D	ISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) □			
6	CITIZENS	HIP OR	PLACE OF ORGANIZATION			
	United Stat	es of An	nerica			
NUM	IBER OF	7	SOLE VOTING POWER			
SH	IARES		-0-			
BENE	FICIALLY	8	SHARED VOTING POWER			
OWI	NED BY		22,152,136			
EACH REPORTING		9	SOLE DISPOSITIVE POWER			
PERSON			-0-			
WITH		10	SHARED DISPOSITIVE POWER			
			22,152,136			
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	22,152,136					
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) □					
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)					
	9.9%*					
14	TYPE OF I	REPORT	ING PERSON			
	IN					

^{*} The calculation assumes that there is a total of 222,661,344 Ordinary Shares outstanding as of April 29, 2016, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Commission on May 6, 2016.

SCHEDULE 13D

This Amendment No. 1 (this "Amendment") amends and supplements the Schedule 13D filed on May 5, 2016 (the "Original Schedule 13D" and, as amended and supplemented by this Amendment, the "Schedule 13D") by TPG Group Holdings (SBS) Advisors, Inc., a Delaware corporation ("Group Advisors"), TPG Advisors VI, Inc., a Delaware corporation ("TPG Advisors VI"), David Bonderman and James G. Coulter with respect to the Ordinary Shares, nominal value \$0.0001 per share, of Endo International plc.

Item 2. Identity and Background.

This Amendment amends and restates the second paragraph of Item 2 of the Original Schedule 13D in its entirety as set forth below:

"Group Advisors is the general partner of TPG Group Holdings (SBS), L.P., a Delaware limited partnership, which is the sole member of TPG Holdings I-A, LLC, a Delaware limited liability company, which is the general partner of TPG Holdings I, L.P., a Delaware limited partnership, which is (i) the sole member of TPG Biotechnology GenPar IV Advisors, LLC, a Delaware limited liability company ("Biotech GenPar IV"), and (ii) the sole shareholder of TPG GenPar VI-AIV Advisors, Inc., a Cayman Islands corporation ("TPG GenPar VI-AIV"). Biotech IV is the general partner of TPG Biotechnology GenPar IV, L.P., a Delaware limited partnership, which is the general partner of TPG Biotechnology Partners IV, L.P., a Delaware limited partnership ("Biotech IV"), which directly holds 226,439 Ordinary Shares. TPG GenPar VI-AIV is the general partner of TPG GenPar VI-AIV, L.P., a Cayman Islands limited partnership, which is the general partner of TPG Partners VI CAI AIV II, L.P., a Cayman Islands limited partnership ("TPG VI CAI AIV II"), which directly holds 4,909,610 Ordinary Shares. TPG Advisors VI is the general partner of each of (i) TPG Sky, L.P., a Delaware limited partnership ("TPG Sky"), which directly holds 13,499,524 Ordinary Shares, and (ii) TPG Sky Co-Invest, L.P., a Delaware limited partnership ("TPG Sky Co-Invest"), which directly holds 13,499,524 Ordinary Shares, and (ii) TPG Funds"), which directly holds 3,516,563 Ordinary Shares."

Item 4. Purpose of Transaction.

This Amendment amends and supplements Item 4 of the Original Schedule 13D by adding the following before the penultimate paragraph thereof:

"Pursuant to the Standstill exception described above:

- On May 19, 2016, certain TPG Funds acquired beneficial ownership of 3,970,000 Ordinary Shares at an average price per share of \$15.1517 pursuant
 to a share forward transaction agreement dated May 17, 2016. This agreement provided for automatic settlement in such Ordinary Shares upon receipt
 of the approval under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, which was received on May 19, 2016.
- On May 20, 2016, certain TPG Funds acquired beneficial ownership of 1,000,000 Ordinary Shares at an average price per share of \$15.3639 pursuant
 to open market purchases.

The purchase of the Ordinary Shares described in the preceding two paragraphs was funded by equity contributions of the limited partners of the relevant TPG Funds."

Item 5. Interest in Securities of the Issuer.

This Amendment amends and restates the second and third paragraphs of Item 2 of the Original Schedule 13D in their entirety as set forth below:

"(a)-(b) The following disclosure assumes there are a total of 222,661,344 Ordinary Shares outstanding as of April 29, 2016, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Commission on May 6, 2016.

Pursuant to Rule 13d-3 under the Act, the Reporting Persons may be deemed to beneficially own 22,152,136 Ordinary Shares, which constitutes approximately 9.9% of the outstanding Ordinary Shares."

Page 7 of 8

SIGNATURE

	After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and
correct.	
Dated: N	May 20, 2016

TPG Group Holdings (SBS) Advisors, Inc.

By: /s/ Clive Bode
Name: Clive Bode
Title: Vice President

TPG Advisors VI, Inc.

By: /s/ Clive Bode
Name: Clive Bode
Title: Vice President

David Bonderman

By: /s/ Clive Bode
Name: Clive Bode
Name: Clive Bode, on behalf of David Bonderman (1)

James G. Coulter

By: /s/ Clive Bode
Name: Clive Bode, on behalf of James G. Coulter (2)

- (1) Clive Bode is signing on behalf of Mr. Bonderman pursuant to an authorization and designation letter dated June 19, 2015, which was previously filed with the Commission as an exhibit to an amendment to Schedule 13D filed by Mr. Bonderman on June 22, 2015 (SEC File No. 005-87680).
- (2) Clive Bode is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated June 19, 2015, which was previously filed with the Commission as an exhibit to an amendment to Schedule 13D filed by Mr. Coulter on June 22, 2015 (SEC File No. 005-87680).